ELUTIA INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 21, 2026, reports on events occurring on August 17, 2026. Elutia Inc. (ELUT), an emerging growth company incorporated in Delaware, completed the sale of substantially all assets related to its SimpliDerm business to Cellution Biologics Inc. The SimpliDerm business, which focused on human acellular dermis (hADM) products for breast reconstruction, constituted substantially all assets of Elutia's Women's Health segment.
Key Financial Metrics and Transaction Details
- Cash Proceeds: $7.7 million paid at closing.
- Contingent Consideration: Up to an additional $3 million potentially payable over the next 18 months, contingent on technology transfer and commercial milestones.
- Price Adjustment: The purchase price is subject to adjustment based on a post-closing inventory valuation.
- Debt Impact: Elutia amended its Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P., to release the lien on the sold assets.
- Financial Statements: Unaudited pro forma consolidated financial information is provided in Exhibit 99.2 but specific revenue, profit, or cash flow figures for the period are not detailed in this filing text.
Material Changes and Agreements
The completion of the sale represents a material disposition of assets. Key contractual obligations arising from the transaction include:
- Non-Competition: A five-year restrictive covenant preventing Elutia from competing in business lines related to human acellular dermis products.
- Transition Services: An agreement to provide post-closing transitional support services to Cellution Biologics for up to six months.
Outlook, Risks, and Contingencies
Management highlights forward-looking risks regarding the final purchase price. The total consideration depends on the outcome of the post-closing inventory valuation and the achievement of specific milestones for the contingent payments. The filing explicitly states that investors should not rely on representations in the Purchase Agreement as characterizations of actual facts, as these may be subject to qualifications and materiality standards differing from those applicable to security holders.
Investor Verification Checklist
- Verify the final purchase price after the post-closing inventory valuation adjustment.
- Monitor the achievement of technology transfer and commercial milestones to determine if the up to $3 million in contingent payments will be realized.
- Review the unaudited pro forma financial information in Exhibit 99.2 to assess the impact of the divestiture on Elutia's remaining financial position.
- Confirm the status of the amended Loan and Security Agreement and any remaining debt obligations.